MedTrace Logo

Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

NCT00413023 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2016-10-28

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

GW679769

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • Argentina
  • Belgium
  • Chile
  • Costa Rica
  • Germany
  • Italy
  • Peru
  • Poland
  • Slovakia
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413023 on ClinicalTrials.gov